INTRODUCTION AND OBJECTIVES: Programmed death ligand 1 (PD-L1) is overexpressed in certain solid tumors, including urothelial cell carcinoma of the bladder. PD-L1 bound to programmed death protein 1 (PD-1) forms a complex which inhibits native T cell immune response against malignant cells. This can be abrogated by targeted immunotherapeutic agents that inhibit formation of this complex. Existing data demonstrates a benefit to administering PD-L1 inhibitor immunotherapy in patients whose immune cells express >1% PD-L1 positivity. One mechanism of 00 immune escape 00 might be the increased production of PD-L1 expression in those cells capable of lymphatic metastasis. The aim of this study was to examine the correlation of PD-L1 staining status between the primary bladder tumor and lymph node metastasis in patients following radical cystectomy.
METHODS: A multi-institutional, retrospective review of prospectively maintained bladder cancer databases identified 69 subjects who underwent radical cystectomy between 2008 and 2015 and were found to have residual cancer in the bladder as well as node-positive disease. The pathology was centrally re-reviewed by a GU pathologist and stained for PD-L1 in both the primary tumor and lymph node specimens. PD-L1 staining >1% was deemed 00 positive 00 and H scores based on percentage of cells involved and intensity of staining for each specimen was determined. Fidelity of PD-L1 status between primary tumors and lymph node metastases was then systematically analyzed.
RESULTS: Positive or negative PD-L1 staining status was preserved between the bladder cancer primary and lymph node metastasis in 78.3% of cases studied. The mean H-score in the bladder tumor primary and lymph node specimens was 52.2 and 49.6, respectively. The interclass correlation coefficient (ICC) between the average bladder and lymph node H-scores was 0.85 (95% CI 0.75-0.91).
CONCLUSIONS: PD-L1 fidelity was preserved in 78.3% of cases in this multi-institutional cohort. While further study is needed to better define the impact of this correlation, extrapolation of this data to the clinical context suggests that treatment failure would not be predominantly explained by phenotypic evolution of the nodal tumor. As neoadjuvant and adjuvant checkpoint inhibitor data matures, clinical application may be guided by PD-L1 status of the primary tumor and associated metastases.
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MP65-08 THE NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR FOR PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER FOLLOWING RADICAL CYSTECTOMY
INTRODUCTION AND OBJECTIVES: Pre-treatment neutrophilto-lymphocyte ratio (NLR) is a marker of systemic inflammation that has been associated with adverse pathology or survival in a variety of malignancies, including urothelial carcinoma of the bladder (UCB) treated with radical cystectomy (RC). However, whether the prognostic value of NLR is retained, or even increased, when measured postoperatively remains not well studied. In this study, we evaluated the association of preoperative and postoperative NLR with oncological outcomes following RC.
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